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Background: Prolonged cough is one of the troublesome symptoms commonly seen in daily
practice. Especially, detection of allergic cough such as bronchial asthma (BA), cough variant
asthma (CVA) and eosinophilic bronchitis without asthma (EB) is important because the prev-
alence of these disorders are high. We previously reported fractional exhaled nitric oxide
(FeNO) can be a non-invasive marker of allergic airway inflammation. We examined whether
FeNO could be applicable for the proper diagnosis of prolonged cough.
Method: About 71 consecutive subjects complaining prolonged cough who gave informed con-
sent for the study were enrolled. FeNO, pulmonary function tests, bronchial hyperresponsive-
ness (BHR), IgE, and eosinophils in induced sputum and peripheral blood were measured. Final
diagnosis of the subjects was 30 with BA, 18 with CVA, 8 with EB, and 15 with other respiratory
disorders (Others).
Result: FeNO had significant correlations with non-specific IgE, mite-specific IgE, FEV/FVC,
BHR, and eosinophils. The level of cedar-specific IgE was significantly higher in subjects with
EB than CVA. FeNO levels in BA and CVA were significantly higher than those in EB and Others.
The optimal cutoff level of FeNO was 38.8 ppb with sensitivity of 79.2% and specificity of 91.3%
for distinguishing BA and CVA from EB and Others.
Conclusion: FeNO could be used as a diagnostic marker of prolonged cough, especially for the
differential diagnosis BA and CVA from EB and others.
ª 2008 Elsevier Ltd. All rights reserved.ma; EB, eosinophilic bronchitis without asthma; FeNO, fractional exhaled nitric oxide; ppb, parts per
in one second; FVC, forced vital capacity; BHR, bronchial hyperresponsiveness; IgE, immunoglobulin
I, confidence interval; ATS, American Thoracic Society; ERS, European Respiratory Society; ROC,
in, minimum dose of methacholine; GERD, gastroesophageal reflux disease.
of Pulmonary Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, Japan.
8 9366.
(S. Sato).
8 Elsevier Ltd. All rights reserved.
FeNO for diagnosing prolonged cough 1453Introduction
Patients with prolonged cough as a chief complaint are
commonly seen in outpatient clinics, however proper
diagnosis is often difficult.1 Morice et al. report that the
most common diagnoses in patients with chronic cough
are cough variant asthma (CVA), sinobronchial syndrome,
and gastroesophageal reflux disease (GERD), followed by
eosinophilic bronchitis without asthma (EB), chronic bron-
chitis, post infectious cough, and ACE inhibitor induced
cough.2 In Japan, the prevalence of CVA, atopic cough,
and sinobronchial syndrome is high, whereas the preva-
lence of GERD as a cause of chronic cough tends to be
low.3 Therefore, detection and diagnosis of allergic cough
(allergic airway inflammatory disorders) as a cause of pro-
longed cough is an important clinical concern.
Airway hyperresponsiveness, pulmonary function tests,
induced sputum, serum IgE, and skin prick tests are com-
monly used to diagnose patients with allergic cough.
Pulmonary function tests are convenient to evaluate
reversibility of airflow limitation, but its sensitivity is low,
since patients withmild diseasemay have normal pulmonary
function. Airway hyperresponsiveness and induced sputum
tests have higher sensitivity, but are more complex to
perform, may trigger bronchoconstriction, and are consid-
ered to be relatively invasive procedures. Blood tests such as
IgE antibodies are useful to screen the presence or absence
of allergies, but they are non-specific for airway pathology.
Fractional exhaled nitric oxide (FeNO) levels are known
to be increased in bronchial asthma (BA).4 Measurement of
FeNO is simple, non-invasive, and potentially useful in eval-
uating allergic airway inflammation.5,6 Disorders with
chronic allergic cough are classified as BA, CVA, and EB.
Each disorder has distinct clinical features, and differential
diagnosis is essential for treatment.7 However, accurate
diagnosis is often difficult. In this article, we investigate
the usefulness of FeNO for the evaluation and differential
diagnosis of allergic airway inflammatory disorders in pa-
tients with prolonged cough.Methods
Subjects
Subjects in this study were 71 consecutive patients who
visited Department of Pulmonary Medicine, Fukushima Med-
ical University Hospital between January 2004 and January
2007, with a chief complaint of prolonged cough or wheezing
lasting more than 3 weeks and gave informed consent for the
study. The patients ranged 20e78 years of age, had no
abnormalities on chest X-ray or CT scan, had no prior history
of treatment for pulmonary disease, and never used oral or
inhaled corticosteroids. The study was approved by the
Ethics Committee at Fukushima Medical University.
Blood tests
Blood tests included peripheral blood eosinophil count,
serum non-specific IgE, and antigen-specific IgE. Radioal-
lergosorbent test for antigen-specific IgE (IgE-RAST) wasperformed for weeds, mites, house dust, cats, dogs, cedar,
cypress, orchard grass, moths, Aspergillus, Candida, and
mixed molds. Non-specific IgE was measured by fluores-
cence enzyme immunoassay (UniCAP; Pharmacia & Up-
john, Uppsala, Sweden). If either the non-specific IgE
concentration was 250 IU/mL, or any antigen-specific
IgE was positive (0.69 UA/mL), the patient was consid-
ered atopic.
Pulmonary function tests
Pulmonary function testing was performed using rolling
seal spirometers (Chestac-11 Cyber S-type; Chest MI,
Inc., Tokyo, Japan) to measure FVC and FEV1. Tests
were performed by experienced respiratory technicians
according to ATS guidelines.8 The FVC and FEV1 are ex-
pressed as percent predicted values. For airway revers-
ibility testing, a positive result was defined as an
improvement in FEV1 of 200 mL and 12% from baseline
when measured 20 min after inhalation of a short-acting
b2 agonist (salbutamol 200 mg from a pressurized inhaler),
or the same improvement after treatment with a long-
acting b2 agonist.
FeNO measurement
FeNO was measured in accordance with ATS/ERS recom-
mendations9 using a chemiluminescence analyzer (Ki-
moto, Osaka, Japan) and is expressed as parts per
billion. The detailed procedure has been described else-
where.5,6 In summary, environmental NO was measured
before and after measurement to make sure that levels
never exceeded 5 ppb. Measurement was performed
with patients in a sitting position and without wearing
a nose clip. From total lung capacity without breath hold-
ing, the patient exhaled at a constant flow of 50 mL/sec.
To eliminate contamination from nasal NO, patients
maintained a constant mouth pressure of 16 cm H2O.
Dead space and nasal NO (expiratory peak) and lower
airway NO (plateau after peak) were automatically dis-
played on a monitor using special software. FeNO was
measured three times, with differences in measured
values within 10%. The mean value of three measure-
ments was used as data for statistical analysis. FeNO
was measured before pulmonary function and airway
hyperresponsiveness testing.
Airway hyperresponsiveness
Airway hyperresponsiveness testing using methacholine
was performed by the Astrograph method (Jupiter 21;
Chest MI, Inc., Tokyo, Japan).10 Patients inhaled methacho-
line diluted in physiologic saline (starting with physiologic
saline only as a control) at gradually increasing concentra-
tions of 49 mg/mL, 98 mg/mL, 195 mg/mL, 390 mg/mL,
781 mg/mL, 1563 mg/mL, 3125 mg/mL, 6250 mg/mL, and
12500 mg/mL, and airway resistance was continuously mea-
sured. A dose-response curve was drawn for methacholine
and airway pressure, and the minimum dose of methacho-
line (Dmin) was calculated as an index of airway respon-
siveness. Positive airway hyperresponsiveness was defined
Table 1 Final diagnosis of the patients with chronic cough
Diagnosis n (%)
Bronchial asthma 30 42.3
Cough variant asthma 18 25.4
Eosinophilic bronchitis
without asthma
8 11.3
Post infectious cough 5 7.0
Post nasal drip 3 4.2
COPD 3 4.2
Chronic bronchitis 2 2.8
Cough with GERD 1 1.4
Sinobronchial syndrome 1 1.4
Total 71 100
1454 S. Sato et al.as a value <12.5 units.11 The total cumulative dose of
methacholine at the end of inhaling the highest dose was
50 units.
Induced sputum tests
Induced sputum was collected using the method described
by Pin et al.12 with inhalation of 5 mL of 5% hypertonic sa-
line using an ultrasonic nebulizer (Nescojet AZ-11, Azwell,
Japan). The sputum samples were stained with Papanico-
laou stain and examined by microscopy. Sputum samples
were judged to be adequate if alveolar macrophages
were present and total percentage of squamous cells was
<10%. On each slide, 400 cells other than squamous cells
were counted. Observers who counted the cells were
blinded to clinical information about the patient. Eosino-
philia in the induced sputum was defined as an eosinophil
count 3% of the total cell count.
Differentiation of allergic chronic cough
Patients with allergic airway inflammation associated with
prolonged cough13 are classified as follows: bronchial
asthma (BA); cough and wheezing for 3 weeks or longer,
sputum eosinophilia, and positive airway hyperresponsive-
ness or presence of reversible airflow limitation, cough
variant asthma (CVA); cough without wheezing for 3 weeks
or longer, sputum eosinophilia, and positive airway hyper-
responsiveness or presence of reversible airflow limita-
tion, eosinophilic bronchitis without asthma (EB); cough
without wheezing for 3 weeks or longer, sputum eosino-
philia, but negative airway hyperresponsiveness and no
reversible airflow limitation.14 Within this classification,
patients with BA and CVA are defined as the asthmatic
group. In patients not meeting these criteria for allergic
airway inflammatory disease, a specific diagnosis was
made, if possible, based on clinical examination, pulmo-
nary function tests, and imaging studies. These are classi-
fied as ‘‘Others’’ disorders.
Statistical analysis
Statistical analysis was performed with SPSS for Windows
(version 8.0; SPSS, Chicago, IL). The data for FeNO,
non-specific IgE, and antigen-specific IgE were not nor-
mally distributed, so these were log transformed before
analysis. Correlations were examined between FeNO and
non-specific IgE, antigen-specific IgE, peripheral blood
eosinophil count, sputum eosinophil count, pulmonary
function (FEV1%), and Dmin by using Spearman rank anal-
ysis. For BA, CVA and EB, individual parameters were
compared. Each parameter was compared using the AN-
OVA test. Patients were classified as having BA, CVA,
EB, or other disorders based on clinical test results, and
mean FeNO was compared between four groups. Finally,
receiver operating characteristics (ROC) curve was
constructed to evaluate the best cutoff level for differ-
entiating asthmatics from other groups. Mean data were
expressed as geometric means and 95% confidence inter-
vals, and a two-tailed p value of less than 0.05 were con-
sidered significant.Results
Subject characteristics
Table 1 shows the breakdown of patients in each group.
Among 71 patients, 30 (42.3%) had BA, 18 (25.4%) had
CVA, 8 (11.3%) had EB, and 15 (21.0%) had other disorders.
The other disorders included post infectious cough in 5
patients, postnasal drip in 3, chronic obstructive pulmonary
disease in 3, chronic bronchitis in 2, GERD in 1, and sino-
bronchial syndrome in 1. There were no subjects with bron-
chiectasis. Table 2 summarizes the characteristics in each
group. No significant differences were present among four
groups in terms of age, sex, height, weight, or smoking
status. Non-smokers were defined as any patient, including
ex-smokers, who did not smoke within 1 month before ini-
tial evaluation. There were 53 patients (74.6%) in the
non-smoking group.
Correlation between FeNO with serum IgE and
pulmonary function
Fig. 1 shows the correlation between FeNO levels with non-
specific IgE and mite-specific IgE. FeNO showed significantly
positive correlations with non-specific IgE (rZ 0.497,
p< 0.001) and mite-specific IgE (rZ 0.342, pZ 0.004).
There was no significant correlation between FeNO and spe-
cific IgE other than for mites (data not shown). FeNO
showed significantly negative correlations with Dmin and
FEV1/FVC (rZ0.567, p< 0.001; r Z 0.447, p< 0.001;
respectively) (Fig. 2). In addition, FeNO showed signifi-
cantly positive correlations with eosinophils in both
induced sputum and peripheral blood (rZ 0.244,
pZ 0.042; rZ 0.376, pZ 0.001; respectively) (Fig. 3).
Comparison of FeNO levels among the four groups
Fig. 4 shows the FeNO levels in each group. The mean FeNO
in each group was: BA 93.5 ppb (95% CI, 72.5e120.7), CVA
46.7 ppb (95% CI, 33.6e64.8), EB 16.4 ppb (95% CI, 10.9e
24.8), and Others 21.2 ppb (95% CI, 15.1e29.7). FeNO in
the BA group was significantly higher than in the CVA
(pZ 0.001), EB (p< 0.001), and Others (p< 0.001) groups.
Table 2 Comparison of individual parameters
BA CVA EB Others
Age (yr) 55.5 (48.9e62.5) 48.2 (39.4e57.0) 45.3 (33.3e57.2) 55.5 (47.5e63.5)
Gender (male/female) 20/10 7/11 4/4 8/7
Height (cm) 162.2 (158.2e166.1) 159.3 (154.6e164.0) 161.6 (155.4e167.9) 159.4 (155.0e163.9)
Body weight (kg) 66.6 (58.5e74.7) 58.0 (51.6e64.4) 67.7 (59.1e76.3) 65.9 (58.7e73.1)
Smoker/non-smoker 8/22 3/15 1/7 5/10
Data are expressed as geometric means and 95% CIs. 95% CIs: 95% confidence intervals.
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the EB (p< 0.001) and Others (p< 0.001) groups. FeNO did
not significantly differ between the EB group and Others
group (pZ 0.316). When analysis was limited to non-
smokers (nZ 53), the mean FeNO was BA 85.6 ppb (95%
CI, 63.5e115), CVA 40.4 ppb (95% CI, 29.4e55.7), EB
17.6 ppb (95% CI, 11.2e27.7), and Others 18.3 ppb (95%
CI, 11.4e29.5). As in the entire study cohort, there were
similar significant differences among the groups.
Comparison of individual parameters in BA,
CVA and EB
Table 3 compares each parameter between the BA, CVA,
and EB group. FeNO was significantly higher in BA and
CVA group (p< 0.001) than in EB group. The percentage
of sputum eosinophils in BA group was significantly higher
than that in EB group (pZ 0.037). But, it did not signifi-
cantly differ between CVA group and EB group. Mite-
specific IgE level was significantly higher in BA group than
in EB group. But, in CVA group the difference was not sta-
tistically significant. On the other hand, cedar-specific IgE
was significantly higher in EB group (pZ 0.02) than in CVA
group.
Cutoff levels to discriminate BA from EB and Others
An ROC curve was constructed to establish a cutoff point to
discriminate between asthmatic (BAþ CVA) and non-asth-
matic (EBþ Others) disorders (Fig. 5). The optimal cutoff
level of FeNO to discriminate between asthmatics and30010010
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Figure 1 Relationships between FeNO and non-specific Ignon-asthmatic disorders was 38.8 ppb (sensitivity of 79.2%
and specificity of 91.3%).
Discussion
In this study, we measured FeNO in patients with chronic
cough but who had no abnormalities on imaging studies.
FeNO showed statistically significant negative correlations
with airway hyperresponsiveness and FEV1/FVC, and posi-
tive correlations with induced sputum and peripheral blood
eosinophil counts, non-specific IgE, and mite-specific IgE.
On analysis of FeNO in each group, we found significantly
higher FeNO levels in BA and CVA group, as compared to
EB group. FeNO did not significantly differ between EB
group and Others group, thus showing absence of a rise in
FeNO in EB patients.
In studies in children,5,15 as well as in adults, there is
a significant positive correlation between FeNO with non-
specific IgE and mite-specific IgE. However, the correlation
in adults is weaker than in children. This probably can be
attributed to a lower prevalence of atopic asthma in adults
than in children. On the other hand, FeNO showed signifi-
cantly positive correlation with peripheral blood and in-
duced sputum eosinophil counts, and significantly
negative correlation, as in a previous study,16 with airway
hyperresponsiveness and FEV1/FVC. Therefore, FeNO may
be useful not only as an index of antigen sensitization,
but also to evaluate the presence or absence of allergic
airway pathology.
Our findings showed a rise in FeNO levels in BA group and
CVA group, but not in EB group, which differs from other30010010
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Figure 2 Relationships between FeNO and Dmin (A), and FeNO and FEV1/FVC (B).
1456 S. Sato et al.reports to date. Only two previous studies have investi-
gated FeNO levels in EB. In one study, Berlyne et al.
measured FeNO in EB patients, irrespective of history of
use or non-use of corticosteroid therapy, and reported
significantly higher levels than in BA patients.17 In another
study, Brightling et al. reported significantly higher FeNO
levels in EB (12 ppb) than in asthma (8.5 ppb).18 EB is a rel-
atively new concept first described by Gibson et al. in 1989.
They defined EB as patients with chronic cough and sputum
eosinophilia, but without bronchial hyperresponsiveness or
reversible airflow limitation.19 However, in diagnosing EB,
Berlyne et al. did not evaluate reversible airflow limitation;
they only evaluated airway hyperresponsiveness to distin-
guish EB from BA. Therefore, patients they diagnosed
with EB may have also included those with CVA. In the study
by Brightling et al., FeNO was higher in EB than in BA
patients. But in their patients with EB, eosinophil counts
were elevated both in bronchoalveolar and bronchial
lavage fluid, and FeNO levels varied widely between 5
ppb and 30 ppb. This may suggest varying degrees of inflam-
mation in the upper to lower airways. In other words, local-
ization and severity of airway inflammation may vary in EB,
thus suggesting different clinical subtypes.30010010
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Figure 3 Relationships between FeNO and eosIn our study, we evaluated airway hyperresponsiveness
and presence or absence of reversible airflow limitation
using a b2 agonist to distinguish EB from CVA. Patients with
EB had no increase in FeNO. In addition, FeNO levels were
higher in BA than in CVA. When we compared individual
parameters between the CVA group and EB group, cedar-
specific IgE was significantly higher in the EB group
(Table 3). Cedar pollen is the most common type of allergic
rhinitis seen in Japan. Japanese cedar pollen granules have
a diameter of 30e40 mm, and most of the inhaled pollen is
deposited in the nasal cavity and upper airway, without
reaching the lower airways.20 Consequently, our EB pa-
tients may have been sensitized to cedar allergen, with in-
halation of the allergen causing relatively localized
eosinophilic inflammation in the upper airways. In other
words, in our patients with EB, eosinophilic airway inflam-
mation was localized, and because of less airway surface
area involvement in FeNO production than in CVA and BA,
the FeNO levels did not increase. As another possibility,
different factors affecting the expression and activation
of the nitric oxide synthase (NOS) in BA and EB could be re-
sponsible for the FeNO production. Further investigation
addressing this issue should be done, for example, using30010010
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Figure 4 Comparison of FeNO levels among four groups. Box
plots for FeNO levels are shown. The thick bar is the median
values, and the shaded box represents the interquartile range.
Outlying points beyond the inner fences are shown individually.
FeNO for diagnosing prolonged cough 1457the method described by Brindicci et al.21 to differentially
measure exhaled NO in the central and peripheral airways,
and the immunohistochemistry of airway biopsy specimen
for the different types of NOS. Furthermore, sputum neu-
trophilia might be another reason of lower FeNO levels in
EB patients. However, in this study, no significant differ-
ences were observed in sputum neutrophils between asth-
matics and EB (data not shown) suggesting that the lower
FeNO levels in EB group in this study may not be due to
the difference in neutrophilic airway inflammation. For
the severity of asthma, only 6 patients were classified asTable 3 Comparison of BA, CVA and EB parameters
BA (nZ 30)
Age (yr) 55.5 (48.6e62.5)
Gender (male/female) 20/10
Height (cm) 162 (158e166)
Body weight (kg) 66.6 (58.5e74.7)
Smoking/non-smoking 8/22
FeNO (ppb) 93.5 (72.4e121)**a
Blood eosinophils (/ml) 187 (81.4e431)
Sputum eosinophil (%) 42.5 (32.8e52.1)*
Non-specific IgE (IU/ml) 239 (137e414)y
Mite-specific IgE (UA/ml) 1.78 (0.78e4.03)
House dust
specific IgE (UA/ml)
1.78 (1.25e3.97)*
Cat specific
IgE (UA/ml)
0.61 (0.35e0.92)
Dog specific
IgE (UA/ml)
0.53 (0.31e0.92)
Cedar-specific IgE (UA/ml) 1.74 (0.80e3.77)
FVC % predicted (%) 94.9 (87.2e103)*
FEV1/FVC (%) 68.4 (64.3e72.4)*
a
Data are expressed as geometric means and 95% CIs.
*p< 0.05 and **p< 0.001 in comparison with EB.
ap< 0.01 in comparison with CVA.severe asthma, the remaining 24 patients were classified
as mild-to-moderate asthma in our patients. Sputum
neutrophil and FeNO did not differ between severe and
mild-to-moderate asthma.
The effect of smoking on FeNO levels in this study should
be discussed. It has been shown that FeNO of steroid naı¨ve
smoker asthmatics is lower than non-smoker asthmatics22
and that generally smoking reduces the levels of FeNO.9
We also observed same results in our previous study.6 How-
ever, in athmatics of our study (including both BA and CVA),
the average levels of FeNO were higher in smoker asth-
matics (nZ 11) than in non-smoker asthmatics (nZ 37)
(112.2 ppb and 63.1 ppb, respectively). Additional analyses
revealed no difference in the percentage of eosinophils be-
tween smoker and non-smoker asthmatics. However, there
was a clear difference in atopic status between two groups.
Nine of 11 smoker asthmatics (81.8%) were atopic, however
22 of 37 non-smoker asthmatics (59.5%) were atopic. Fur-
thermore, the average level of non-specific IgE was signifi-
cantly higher in smoker asthmatics than non-smoker
asthmatics (404 IU/mL, 105 IU/mL, respectively, p< 0.05).
These results suggest that the difference in atopic status
might explain the higher FeNO levels in smoker asthmatics
in this study.
In studies to date, about 30e40% of patients with CVA go
on to develop BA,23 and airway remodeling begins at an
early stage.24 In EB, the presence of airway remodeling
has not been investigated, but in a follow-up study by Berry
et al., patients usually had a stable course without progres-
sion to bronchial asthma.25 Therefore, differential diagno-
sis between EB and asthma is clinically important in terms
of treatment and prognosis. But Berry et al. have also re-
ported that some EB patients developed bronchial asthma.
This further raise the possible existence of EB clinicalCVA (nZ 18) EB (nZ 8)
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Figure 5 ROC curve for FeNO to distinguish asthmatic disor-
ders from non-asthmatic disorders; data labels show the se-
lected cutoff points of FeNO levels. The optimal cutoff level
of FeNO was 38.8 ppb, sensitivity was 79.2% and specificity
was 91.3%.
1458 S. Sato et al.subtypes as mentioned previously. It is possible that pa-
tients with EB who have higher FeNO levels, in other words,
more upper to lower airway inflammation, may go on to de-
velop bronchial asthma. Further research concerning this
issue is also needed.
Finally, the optimal cutoff level of FeNO for distinguish-
ing asthmatics from non-asthmatics was 38.8 ppb (sensitiv-
ity 79.2%, specificity 91.3%). Several cutoff levels of FeNO,
in conjunction with other tests, have been recommended in
the diagnosis of BA.26 Using measurement of FeNO alone,
a cutoff point of 36 ppb (sensitivity 78%, specificity 60%)
has also been reported.27 In addition, in patients with
chronic cough, Chatkin et al. used FeNO cutoff level of 30
ppb (sensitivity 75%, specificity 87%) to define their asth-
matic group (including both BA and CVA).28 Thus, our
results support other published findings.
In conclusion, FeNO could be used as a diagnostic marker
of prolonged cough. In addition, it could also be useful to
distinguish CVA from EB which have both the same eosin-
ophilic airway inflammation.
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